Second clinical program entering Phase 2 with data expected 2026BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest ...

Increase awareness about colorectal cancer to promote early diagnosis and treatment, reducing mortality rates worldwide.

The American Gastroenterological Association (AGA) released a new clinical guideline making no recommendation—for or ...

As part of the colorectal (large intestine) cancer screening program, which is provided free of charge every two years for ...

The (AGA) released a new clinical guideline making no recommendation - for or against - the use of computer-aided detection ...

has announced that the U.S. FDA has granted a "Study May Proceed" letter for their Phase 2 clinical trial of TPST-1495, a novel dual receptor inhibitor aimed at treating Familial Adenomatous ...

Biodexa Pharmaceuticals (BDRX) is making progress in readying the launch of a phase 3 trial for eRapa, its proprietary encapsulated form of ...

The planned Phase 2 study will evaluate the efficacy and safety of TPST-1495 in patients with Familial Adenomatous Polyposis (FAP) who have previously undergone colectomy. The primary efficacy ...

AI-assisted colonoscopy detects more polyps, but whether that reduces cancer rates is uncertain. The American ...

Biodexa Pharmaceuticals announced a successful Type C meeting with the FDA, which has cleared the way to finalize the Phase 3 protocol for its drug eRapa in treating familial adenomatous polyposis ...